Evogen Study at 2017 AES Annual Meeting Identifies New Proteomic Biomarkers for Diagnosis of Epileptic Seizures

Evogen Study at 2017 AES Annual Meeting Identifies New Proteomic Biomarkers for Diagnosis of Epileptic Seizures

PR Newswire (paid press release):

PHILADELPHIA and WASHINGTON, Dec. 2, 2017 /PRNewswire/ — Evogen, Inc., a leader in proteomics and genomics-based testing for improved diagnosis and treatment of neurological disorders, today reported that a clinical study to be presented at the 2017 Annual Meeting of the American…

Click here to read the full article.